These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 39131709)

  • 1. A Machine Learning Model to Predict Risk for Hepatocellular Carcinoma in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Sarkar S; Alurwar A; Ly C; Piao C; Donde R; Wang CJ; Meyers FJ
    Gastro Hep Adv; 2024; 3(4):498-505. PubMed ID: 39131709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Rodriguez LA; Schmittdiel JA; Liu L; Macdonald BA; Balasubramanian S; Chai KP; Seo SI; Mukhtar N; Levin TR; Saxena V
    JAMA Netw Open; 2024 Jul; 7(7):e2421019. PubMed ID: 38990573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.
    Park IG; Yoon SJ; Won SM; Oh KK; Hyun JY; Suk KT; Lee U
    Sci Rep; 2024 Jul; 14(1):16122. PubMed ID: 38997279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Metabolic-Dysfunction-Associated Steatotic Liver Disease and Hepatic Cancer: Current Concepts and Future Challenges.
    Bader H; Yamin S; Alshahwan H; Farraj H; Maghnam J; Abu Omar Y
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892843
    [No Abstract]   [Full Text] [Related]  

  • 7. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
    Rinella ME; Lazarus JV; Ratziu V; Francque SM; Sanyal AJ; Kanwal F; Romero D; Abdelmalek MF; Anstee QM; Arab JP; Arrese M; Bataller R; Beuers U; Boursier J; Bugianesi E; Byrne CD; Castro Narro GE; Chowdhury A; Cortez-Pinto H; Cryer DR; Cusi K; El-Kassas M; Klein S; Eskridge W; Fan J; Gawrieh S; Guy CD; Harrison SA; Kim SU; Koot BG; Korenjak M; Kowdley KV; Lacaille F; Loomba R; Mitchell-Thain R; Morgan TR; Powell EE; Roden M; Romero-Gómez M; Silva M; Singh SP; Sookoian SC; Spearman CW; Tiniakos D; Valenti L; Vos MB; Wong VW; Xanthakos S; Yilmaz Y; Younossi Z; Hobbs A; Villota-Rivas M; Newsome PN;
    Hepatology; 2023 Dec; 78(6):1966-1986. PubMed ID: 37363821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
    Chang D; Truong E; Mena EA; Pacheco F; Wong M; Guindi M; Todo TT; Noureddin N; Ayoub W; Yang JD; Kim IK; Kohli A; Alkhouri N; Harrison S; Noureddin M
    Hepatology; 2023 Feb; 77(2):546-557. PubMed ID: 35809234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
    Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
    World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A predictive model for the diagnosis of non-alcoholic fatty liver disease based on an integrated machine learning method.
    Ma X; Yang C; Liang K; Sun B; Jin W; Chen L; Dong M; Liu S; Xin Y; Zhuang L
    Am J Transl Res; 2021; 13(11):12704-12713. PubMed ID: 34956485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic steatosis is associated with anthropometry, cardio-metabolic disease risk, sex, age and urbanisation, but not with ethnicity in adult Kenyans.
    Kastberg SE; Lund HS; De Lucia-Rolfe E; Kaduka LU; Boit MK; Corpeleijn E; Friis H; Bernard S; Paquette M; Baass A; Rasmussen JJ; Christensen DL
    Trop Med Int Health; 2022 Jan; 27(1):49-57. PubMed ID: 34704339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study.
    Pinyopornpanish K; Khoudari G; Saleh MA; Angkurawaranon C; Pinyopornpanish K; Mansoor E; Dasarathy S; McCullough A
    BMC Gastroenterol; 2021 Oct; 21(1):394. PubMed ID: 34674650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of remnant cholesterol with nonalcoholic fatty liver disease: a general population-based study.
    Zou Y; Lan J; Zhong Y; Yang S; Zhang H; Xie G
    Lipids Health Dis; 2021 Oct; 20(1):139. PubMed ID: 34657611
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.